Muscle Preservation on GLP-1 Medications: What the Research Says You Must Do

Here is a number that should change how every man on a GLP-1 medication thinks about his treatment: in clinical trials lasting 68 to 72 weeks, participants using semaglutide or tirzepatide lost 10% or more of their skeletal muscle mass. According to researchers writing in Obesity Reviews, that figure is roughly equivalent to 20 years of age-related muscle loss, compressed into a single year of treatment. Read that again. Twenty years. The medications are working — the weight is coming off — but without the right countermeasures, a significant portion of what you’re losing isn’t fat. It’s the metabolically active, strength-generating, longevity-protecting tissue that keeps you functional, lean, and healthy for decades to come.

This is not a reason to avoid GLP-1 receptor agonists. The cardiometabolic benefits of these medications are well-documented, and the scale of obesity-related disease they address is enormous. But it is a reason to treat muscle preservation as a non-negotiable clinical priority — not an afterthought — from the moment you start therapy. The research is unambiguous on what the threats are, and increasingly clear on how to counter them.

Why GLP-1 Medications Put Your Muscle at Risk

To understand the problem, you need to understand what happens physiologically during rapid, calorie-restriction-driven weight loss. When you are in a sustained caloric deficit — which is precisely the mechanism by which GLP-1 agonists like semaglutide and tirzepatide produce their effects — your body doesn’t exclusively draw on fat stores. It also catabolizes lean tissue, particularly skeletal muscle, to meet its energy demands. Research published in Metabolism: Clinical and Experimental found that over 25% of total weight lost from both bariatric surgery and incretin-based pharmacotherapy typically comes from fat-free mass, including skeletal muscle. That proportion rises when protein intake is inadequate or resistance training is absent.

The biological machinery driving this loss involves the myostatin-activin-follistatin-inhibin system — a hormonal network originally studied in reproductive biology that turns out to be critically involved in regulating muscle and bone mass during states of negative energy balance. Myostatin and activins promote muscle degradation; follistatin acts as a natural brake on that process. During aggressive caloric restriction, this system can tip toward catabolism, accelerating lean mass loss beyond what simple energy deficit alone would predict. Add to this the fact that a narrative review in Diabetes Care describes the lean mass loss from incretin therapy as approximately 10% of body weight or around 6 kilograms — comparable to a decade or more of normal aging — and the stakes become viscerally clear.

For older men, those with pre-existing low muscle mass, or anyone who already trends toward sedentary behavior, the downstream consequences are particularly serious. A 2026 review in Acta Diabetologica documents how skeletal muscle wasting worsens insulin resistance, accelerates cardiometabolic decline, impairs mobility, and increases mortality risk — the very outcomes GLP-1 therapy is supposed to help prevent. Losing muscle while on these medications doesn’t just undermine your physique. It can undermine the entire therapeutic goal.

The Two Pillars That Actually Protect Your Muscle

The good news is that the research doesn’t just identify the problem — it points clearly to solutions. Two interventions emerge from the literature with consistent, compelling evidence: resistance training and adequate protein intake. Neither is optional. Neither works as well without the other.

On the exercise side, the data is striking. The Diabetes Care review found that supervised resistance training programs lasting more than 10 weeks produced average lean mass increases of approximately 3 kilograms and strength gains of around 25% in men and women. That’s not a marginal benefit — that’s meaningful biological recalibration. The researchers explicitly propose that tailored resistance exercise training be recommended as a standard adjunct to incretin therapy, not an optional lifestyle suggestion. A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society — published in Obesity in 2025 — echoes this directly, recommending that body composition assessment, muscle strength evaluation, and structured resistance training be integrated into GLP-1 treatment protocols from the outset.

In practical terms, this means lifting weights — with real load, real progressive overload, and real frequency. Three to four sessions per week targeting major muscle groups (legs, back, chest, shoulders, arms) is a reasonable starting point. Compound movements like squats, deadlifts, rows, and presses recruit the most muscle fiber and generate the strongest anabolic signal. The goal is not to burn calories during the workout. The goal is to send a biological message that muscle tissue is being actively used and must be retained. Your body responds to demand. Remove the demand, and even a GLP-1 medication won’t stop the loss.

Protein is the other half of this equation. The Obesity Reviews paper is explicit: nutrition therapy during incretin-mimetic drug use must ensure adequate intake of high-quality protein, and may require oral nutritional supplementation given how significantly GLP-1 medications reduce appetite and overall food intake. This is a real-world problem — men on these medications often find they simply aren’t hungry, making it genuinely difficult to hit protein targets through food alone. A practical target used across most clinical guidelines is 1.2 to 1.6 grams of protein per kilogram of body weight per day, with some practitioners recommending up to 2.0 grams per kilogram for men actively resistance training during caloric restriction. Leucine-rich sources — animal proteins, whey, eggs — appear to be most effective at stimulating muscle protein synthesis. If appetite suppression is preventing you from hitting these numbers through whole food, a high-quality protein supplement isn’t a shortcut. It’s a clinical necessity.

Micronutrient status also warrants attention. The same 2025 joint advisory flags nutritional deficiencies as a significant and underappreciated complication of GLP-1 therapy, driven by the dramatic reduction in overall caloric intake. Vitamin D, magnesium, zinc, and B vitamins all play roles in muscle metabolism, protein synthesis, and hormonal function. A comprehensive blood panel at baseline — and periodic monitoring during treatment — gives you the information you need to address deficiencies before they compound muscle loss.

There is also emerging pharmacological interest in compounds that target the myostatin-activin pathway directly. Agents like bimagrumab, trevogrumab, and garetosmab — which inhibit the signals that drive muscle degradation — have shown early promise in preserving or even increasing lean mass during weight loss, either alone or in combination with incretin therapy. Researchers in Metabolism describe these as potentially transformative for body composition outcomes, though well-designed long-term studies are still needed before they enter routine clinical use. For now, they represent a horizon worth watching — particularly for older men or those with pre-existing sarcopenia risk.

What This Means For You

GLP-1 medications are powerful tools. Used correctly, they can produce a level of weight loss that lifestyle intervention alone rarely achieves — and they carry real cardiovascular and metabolic benefits. But powerful tools require skilled use. The research published across multiple journals and professional societies in the past two years has delivered a consistent message: taking a GLP-1 medication without prioritizing resistance training and protein intake is leaving a significant portion of the therapeutic benefit on the table, while simultaneously accepting a risk — muscle loss at the scale of decades of aging — that is largely preventable.

If you are on one of these medications, treat your lifting sessions and your protein targets with the same seriousness you give your injections. If your clinician hasn’t discussed muscle preservation with you, bring this research to your next appointment. The medications will do their job. Your job is to make sure what you’re losing is fat — and what you’re keeping is everything else.